Month: March 2012

Abraham Watkins

Generic Drugs Deserve No Greater Protection than Name-Brand Drugs

In a recent editorial piece, the New York Times articulated what injured victims and plaintiffs lawyers have been saying for the last year – Congress should not allow generic drug manufacturers special protections when those manufacturers fail to warn patients of the generic drug’s dangers. Last year, the United States Supreme Court ruled that although…

Read More
Abraham Watkins

Unregulated Pipelines Lead to Wrongful Deaths

Contrary to popular belief, not all oil and gas pipelines are strictly regulated. In fact, pipelines classified as “gathering” pipelines, which transport gas from well fields to transmission lines, often face less strict safety rules. And depending on how rural their location, such pipelines might not be regulated at all. Federal regulators are trying to…

Read More
Abraham Watkins

Recalled St. Jude’s Heart Wires May Have More Risky Defects

According to a recent Bloomberg article, a study found that the recalled St. Jude Medical Inc. (“St. Jude”) wires, still in use to connect life-saving defibrillators to the hearts of 79,000 patients, had multiple defects that led to melted conductors, electrical abnormalities, and shocks. St. Jude stopped selling its Riata wires in December 2010, and…

Read More
Abraham Watkins

Fungal Eye Infections Prompt Brilliant Blue G Recall

The United States Food & Drug Administration (FDA) has announced an urgent recall of Brilliant Blue G, distributed by Franck’s Compounding Lab in Ocala, Florida. The recall has issued on March 9, 2012. According to the recall notice, Brilliant Blue G has been associated with fungal infections of the eye. According to the pharmacy, lots…

Read More